MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 893 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
LZTR1-KRAS modulator 1
CAS:LZTR1-KRAS modulator 1 is a regulator of the KRAS-LZTR1 interaction, enhancing the recruitment of the LZTR1-KRAS complex.Fórmula:C11H11Cl2NOCor e Forma:SolidPeso molecular:244.12KRAS G12C inhibitor 20
CAS:KRAS G12C inhibitor 20 is a KRAS G12C inhibitor.Fórmula:C33H37ClFN7O3Cor e Forma:SolidPeso molecular:634.14KRAS G12D inhibitor 26
CAS:KRAS G12D inhibitor 26 (Compound 64B) is an inhibitor of KRAS G12D with an IC50 ≤ 100 nM.Fórmula:C35H44ClFN8O2Pureza:99.93%Cor e Forma:SolidPeso molecular:663.23KRAS G12D inhibitor 9
CAS:KRAS G12D inhibitor 9 targets RAS protein, key in growth, showing promise against KRAS G12D cancer.Fórmula:C33H43N7O2Cor e Forma:SolidPeso molecular:569.74Refametinib R enantiomer
CAS:Refametinib R enantiomer (RDEA119 R enantiomer) is an MEK inhibitor with an EC50 of 2.0-15 nM.Refametinib (R enantiomer) has anticancer activity and can be used
Fórmula:C19H20F3IN2O5SPureza:99.86%Cor e Forma:SolidPeso molecular:572.34KRAS G12D inhibitor 11
CAS:KRAS G12D inhibitor 11 targets KRAS G12D in cancer research (patent WO2021108683A1, compound 52).Fórmula:C29H38BN5O3Cor e Forma:SolidPeso molecular:515.45KRAS inhibitor-34
CAS:KRAS inhibitor-34 (compound 27) is a KRAS inhibitor with an IC50 of 6.4 nM and is utilized in oncological research.Fórmula:C43H41F3N6O3Cor e Forma:SolidPeso molecular:746.82KRAS inhibitor-37
CAS:KRAS inhibitor-37 (compound 2) is a potent inhibitor of KRAS, exhibiting low dissociation constants (KD) with various KRAS mutations: wild type (0.004 nM), G12D (0.041 nM), G12C (0.019 nM), and G12V (0.144 nM). This compound effectively inhibits cell proliferation, demonstrating half-maximal inhibitory concentrations (IC50) ranging from <2 nM to 14 nM in H358, SW620, and PANC08.13 cell lines. KRAS inhibitor-37 holds potential for cancer research applications.Fórmula:C32H33ClFN7O3Cor e Forma:SolidPeso molecular:618.10(S)-JDQ-443
CAS:(S)-JDQ-443, an isomer of JDQ-443, is a selective, potent oral KRAS G12C inhibitor with antitumor properties.Fórmula:C29H28ClN7OCor e Forma:SolidPeso molecular:526.03SOF-436
CAS:SOF-436 is a KRAS inhibitor that can suppress SOS1-mediated KRAS nucleotide exchange (IC50 = 60 μM) and inhibit the interaction between KRAS and the effector protein RAF. SOF-436 is applicable to cancer research.Fórmula:C15H13F2NO4S2Cor e Forma:SolidPeso molecular:373.395JAK3-IN-13
JAK3-IN-13: Oral JAK3 inhibitor, selective & potent. Acts on NK1, JNK2, JNK3, Tyk2. Anti-tumor. IC50: JNK3, 8 nM; Tyk2, 365 nM; JNK2, 2039 nM; NK1, 4728 nM.Fórmula:C25H33ClN6O5Cor e Forma:SolidPeso molecular:533.02pan-KRAS degrader 1
CAS:Pan-KRAS degrader 1 (Compound 1) is a broad-spectrum KRAS degrader, exhibiting an inhibitory constant Ki value of 25 nM against KRASG12V as determined by surface plasmon resonance (SPR). Additionally, this compound demonstrates antitumor activity.Fórmula:C22H26N8OSCor e Forma:SolidPeso molecular:450.56J-104871
CAS:J-104871 (UNII-6137X5QNJF) is an FTase inhibitor that inhibits tumor growth in nude mice transplanted with activated H-ras-transformed NIH3T3 cells.Fórmula:C38H32N2O12Pureza:98%Cor e Forma:SolidPeso molecular:708.67KRAS G12D inhibitor 16
CAS:KRAS G12D inhibitor 16 targets KRAS G12D with IC50 of 0.7 nM and mutant form at 0.35 μM, useful in various cancer studies.Fórmula:C32H39IN6O3Cor e Forma:SolidPeso molecular:682.59ERK-IN-2
CAS:ERK-IN-2, an ERK2 inhibitor, exhibits an IC50 value of 1.8 nM. At doses greater than 10 μM, it may induce off-target toxicity and/or activity [1].Fórmula:C16H18ClN5O2Pureza:98%Cor e Forma:SolidPeso molecular:347.80Brimarafenib
CAS:Brimarafenib is a selective RAF dimerization inhibitor, which can inhibit BRAF and CRAF, and exhibits inhibitory effects on a variety of RAF mutations.Fórmula:C24H17F3N4O4Pureza:98.32%Cor e Forma:SolidPeso molecular:482.41MRTX849 acid
CAS:MRTX849 acid, used to make PROTAC LC-2, effectively degrades KRAS G12C at 0.25-0.76 μM DC50.Fórmula:C34H37ClFN7O4Cor e Forma:SolidPeso molecular:662.16KRASG12C IN-13
CAS:KRASG12C IN-13 (LY3499446), a potent inhibitor of KRAS G12C, shows potential in the study of advanced solid tumors, specifically non-small cell lung cancer and colorectal cancer.Fórmula:C22H17ClF2N6OSCor e Forma:SolidPeso molecular:486.93KRAS G12C inhibitor 33
CAS:KRAS G12C inhibitor 33 is a KRAS G12C inhibitor that can be used to study cancer.Fórmula:C30H33N7O3Cor e Forma:SolidPeso molecular:539.63KRAS ligand 5
CAS:KRAS ligand 5 acts as the target protein ligand for PROTACK-Ras Degrader-3, which specifically targets and degrades mutated KRAS proteins.Fórmula:C30H30F2N4O4Cor e Forma:SolidPeso molecular:548.58
